FDA has accepted the supplemental New Drug Application for Augtyro (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity.Â
MD Anderson Cancer Center and C-Biomex Ltd. have formed a strategic research collaboration agreement to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
BioNTech SE, a next-generation immunotherapy company, and Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, have formed collaboration with the aim of advancing both companies’ autologous CAR T programs towards commercialization, pending regulatory authorizations.Â
As the likelihood of a flat budget increases for the 2024 fiscal year, NCI will have difficulty maintaining its current programs, the institute’s new director Kimryn Rathmell said in her inaugural NCI director’s report to members of the National Cancer Advisory Board Feb. 8.
The House Committee on Energy and Commerce has issued a subpoena to require NIH Director Monica Bertagnolli to provide information related to NIH’s handling of allegations of sexual harassment and workplace misconduct.
NIH has until Feb. 20 to comply with a congressional subpoena that directs NIH Director Monica Bertagnolli to produce internal documents, including reports and whistleblower complaints that could shed light on whether NIH is adequately responding to complaints of workplace misconduct and sexual harassment.
As artificial intelligence becomes an indispensable tool in cancer research, drug sponsors and researchers should focus on building and utilizing rich real-world evidence databases that can be used to complement clinical trials.
For many women, a confirmation of pregnancy tends to evoke numerous emotions: excitement, shock, nervousness, joy, gratitude, and sometimes, even surprise. It is a moment dreamed, prayed, and planned for—but not for all.
Karen Lu was named executive vice president and physician-in-chief at Moffitt Cancer Center.
Nobel laureate Phillip A. Sharp, who has chaired the Stand Up To Cancer scientific advisory committee since SU2C launched in 2008 is transitioning to emeritus status at the organization.
